ArticleAnnals of medicine and surgery (2012)2025

Fazirsiran for the treatment of alpha-1 antitrypsin deficiency-associated liver disease findings from the SEQUOIA phase 2 trial.

Talha Liaquat et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.